Click on the following links to read the articles:

UOB KayHian Keeps Sinopharm At Buy, Target HK$26 (12-7-2011)

UBS Cuts Sinopharm Target To HK$25 (11-10-2011)

Goldman Sachs Cuts Target Prices for China Healthcare Shares (7-15-2011)

Credit Suisse Says China Is The Third Largest Pharmaceutical Market Globally; Healthcare Plays’ Declines Overdone (7-1-2011)

JP Morgan Ups Sinopharm To Overweight, Target HK$32.00 (2-26-2011)

Nomura Says Value Re-emerges in China Healthcare Stocks (2-18-2011)

GuocoCapital Keeps Sinopharm At Buy;Target Price HK$30.60 (2-9-2011)

Nomura Keeps Sinopharm Neutral and Cuts Its Target to HK$29.00 (12-15-2010)

Goldman Sachs Bullish on China Healthcare Sector; Revised Sector Players’ Targets (11-25-2010)

Nomura Starts Coverage of Sinopharm with Neutral Rating with Target at HK$32.5 (11-6-2010)